Podcasts about Aegean

To support the show, for ad free episodes and exclusive content sign up here.On this episode George and Maria discuss some islands many of you have been asking for episodes on and those are Paros, Naxos and the small Cyclades.Tune in to hear more about these islands and if you would like us to come back with more episodes on them, get in touch!Greek phrase shared on the episode: The colors of the Aegean are unique: Ta chró̱mata tou Aigaíou eínai monadiká. (In Greek: Τα χρώματα του Αιγαίου είναι μοναδικά.)Available Itineraries/Top Picks:Athens, Santorini, Paros (+ Antiparos) and the Athens RivieraParos (+ Antiparos) ItineraryParos (+ Antiparos) e-mapFurther Podcast Listening:AmorgosAthens - A Greek-endAstypalaia Part 1 & Part 2Greek Islands for Solo TravellersThe Athens RivieraTop Greek Islands without a carMy Greek EasterExpress Skopelitis: https://www.smallcycladeslines.gr/en/home/Do you need help planning your trip to Greece? Then book a travel consultation with Maria. Click here.Do you need help planning your trip to Greece? Then book a travel consultation with Maria. Click here.Visit the website: www.mygreekis.land for inspiration, itineraries and more.Follow us on Instagram and TikTok @mygreekislandSubscribe and leave a rating and review!To support the show further sign up to Patreon for ad free episodes and exclusive content here.There are 227 inhabited Greek Islands, which one will YOU visit next?#MGIPODCAST Hosted on Acast. See acast.com/privacy for more information.

WWW.ADVENTUREFREAKSSS.COM Find your Ideal Destination Here:https://adventurefreaksss.com/ideal-destination-finder/================================= How to work with me: =================================

Drift into deep relaxation with the soothing rhythm of Aegean waves and the gentle shimmer of windchimes on a coastal breeze. This tranquil soundscape evokes the warmth of a Greek shoreline and is perfect for sleep, meditation, or unwinding at the end of the day. This podcast is entirely independent, and your support helps keep it going. When you like, share, or leave a comment, it tells podcast platforms that people value this show, which enables it to reach a wider audience. These small actions make a big difference in helping the podcast grow. Other ways you can support the show: Shop Your Sleep Guru Podcast exclusive "Licensed to Chill" T-shirts and baseball caps HERE: https://your-sleep-guru-podcast.printify.me/  created especially for you!

Each week Hot off the Wire looks at a variety of stories in business, science, health and more. This week's headlines include: COVID-19 vaccines may help some cancer patients fight tumors. ICE's use of full-body restraints during deportations raises concerns over inhumane treatment. Most Americans are concerned about higher health care costs next year, an AP-NORC poll finds. Disney+ and Hulu cancellations rose after ABC briefly pulled 'Jimmy Kimmel Live!'. What Americans think about legal sports betting, according to recent polls. Coast Guard audio captures stranded family's mayday call. 'Our ship burned while we were sleeping'. Another US strike in Caribbean targets alleged drug-running boat, killing 6, Hegseth says. US is sending an aircraft carrier to Latin America in major escalation of military buildup. Trump says he's ending trade talks with Canada over TV ads. Social Security recipients get a 2.8% cost-of-living boost in 2026, average of $56 per month. US inflation stays elevated but prices rose less than feared last month. North Carolina adopts new Trump-backed US House districts aimed at gaining a Republican seat. 14 migrants dead after dinghy sinks in the Aegean off Turkey's coast. EU accuses Meta and TikTok of breaching transparency rules. Israeli man's sentence over illegal development in Cyprus' breakaway north sends a stark warning. Japan's new leader vows to further bolster defense buildup and spending as regional tensions rise. What to know about Ireland's election as the country votes for a new president. Giant floating pumpkin races draw thousands to annual event in Oregon. Rare dinosaur mummies help scientists recreate their prehistoric lives. Chiefs cornerback Jaylen Watson opens up about his underdog story. On this week's AP Religion Roundup, King Charles visits the Vatican and Venezuela receives its first Catholic saint. —The Associated Press About this program Host Terry Lipshetz is managing editor of the national newsroom for Lee Enterprises. Besides producing the daily Hot off the Wire news podcast, Terry conducts periodic interviews for this Behind the Headlines program, co-hosts the Streamed & Screened movies and television program and is the former producer of Across the Sky, a podcast dedicated to weather and climate. Theme music The News Tonight, used under license from Soundstripe. YouTube clearance: ZR2MOTROGI4XAHRX

AP correspondent Laurence Brooks reports on the death of 14 migrants after their dhingy sank off Turkey's coast.

Earlier this month we saw Turkey issue a NAVTEX, or a navigational text message warning, for research in the Aegean Sea, a provocative move called out by Greece. This has once again put Turkey's disregard for international law and contempt for Greece's sovereignty in the spotlight. Elizabeth Samson, an international lawyer and Writing Fellow at the Middle East Forum whose work has appeared in major outlets like the New York Times and the Wall Street Journal, joins Thanos Davelis as we dig into why it's important to call out Turkey's spurious claims over the Aegean.You can read the articles we discuss on our podcast here:Europe and United States Must Deny Turkey's Spurious Claims Over the AegeanGaza reconstruction: Cyprus has a planSenate Foreign Relations Committee extends lifting of Cyprus arms embargo from annual renewal period to 5 year periodBipartisan US push to extend Cyprus defense access

Empires can lose in stages—and the moments in between can matter most. We dive into the chain that turned Xerxes' massive gamble into Greek momentum: the trap at Salamis, the phalanx at Plataea, and the “forgotten victory” at Mycale that shifted the war from survival to liberation. Step by step, a divided world of city-states learned to think as one, using geography, coalition discipline, and psychological pressure to unmake Persian dominance of the Aegean.We start with the strategic stakes of 480–479 BCE, when Athens and Sparta put rivalry on hold to exploit narrow seas and favourable ground. Salamis shows how triremes, tight channels, and local knowledge shattered a larger fleet and denied Persia the supply lines that kept its army viable. Plataea follows with a land reckoning: Pausanias' coalition absorbed missile fire, closed ranks, and broke Mardonius' force, clearing central Greece and puncturing the myth of Persian inevitability.Then comes Mycale on the Ionian coast, where the meaning of victory changes. Persian ships beached, Ionian units peeled away, and Greek hoplites stormed fortified positions—liberating cities that had long lived under satrapal rule. Near-simultaneous success at Plataea and Mycale delivered a morale shock the Persians couldn't absorb and gave the Greeks ports, partners, and purpose. The result: a transition from defence to projection, the seeds of the Delian League, and a lasting story about unity, freedom, and the power of coordinated land–sea strategy.Support the show

Send us a textThe first portrayal of the Philistines can be seen in the reliefs of the Medinet Habu monument. It shows their warriors, but also their women and children on ox-carts. They came to conquer, but also to live. They fought and contributed culturally, bringing their influences from the Aegean. But were they just a bunch of foreign invaders, or were they migrants integrating into the local culture? Support the show

No one was like him, terrible were his crimes… Where was Alexander the Great born, and who were his parents? What drove him to go beyond the Aegean empire he had already carved out for himself, and conquer lands beyond the limits of the Greek world? Why did Alexander eventually turn back, after ten years of conquest? And, how much of his legend is actually true?  In the second episode of this exclusive new series on four of the most iconic subjects from classical antiquity, Tom is joined again by the world renowned classicist, Mary Beard, to discuss one of history's most famous men: Alexander the Great….hero or villain?  **To hear the full episode, and all the other exclusive new episodes from Mary and Tom's ancient history series, coming out every Friday for the next four weeks, join The Rest is History Club at ⁠therestishistory.com⁠** _______ Twitter:@TheRestHistory @holland_tom @dcsandbrook Video Editor: Jack Meek  Social Producer: Harry Balden Assistant Producer: Aaliyah Akude  Producer: Tabby Syrett Senior Producer: Theo Young-Smith Learn more about your ad choices. Visit podcastchoices.com/adchoices

As efforts continue to resolve Israel's war in Gaza, the conflict is threatening to destabilise the wider region. A rare joint naval exercise between once-rivals Turkey and Egypt is being seen as a warning to Israel, as long-standing alliances shift and new rival partnerships take shape across the Eastern Mediterranean. After a 13-year break, Turkish and Egyptian warships last week carried out a major naval drill in the Eastern Mediterranean. The exercise is the latest step in repairing ties after years of tension that began when Egyptian President Abdel Fattah al-Sisi ousted Mohamed Morsi, a close ally of Turkish leader Recep Tayyip Erdogan. “It marks the consolidation of the improvement in relations,” said Serhat Guvenc, professor of international relations at Kadir Has University in Istanbul, adding the drill sent “a powerful message to Israel of a new alignment”. Guvenc said naval drills in the eastern Mediterranean have typically involved Cyprus, Greece and Israel, but this time Egypt broke with those countries, signalling it was no longer part of the anti-Turkey camp in the region. Erdogan's Washington visit exposes limits of his rapport with Trump Shift in alliances The Turkish-Egyptian exercise follows years in which Cairo built strong ties with Ankara's rivals in the region. The shift has not gone unnoticed in Israel. “Definitely, this is a major event that Turkey and Egypt have conducted a naval exercise after so many years,” said Gallia Lindenstrauss, an Israeli foreign policy specialist at the Institute for National Security Studies in Tel Aviv. The joint drill comes as Ankara has expanded and modernised its navy in recent years. Lindenstrauss said this has unsettled some of Turkey's neighbours, giving Israel common ground with Greece and Cyprus. “Some of them also have quite big disputes with Turkey, such as Cyprus and Greece,” she said. “Greece and Cyprus relations with Israel have been developing since 2010. We've seen a lot of military drills together. We saw weapons procurements between the three actors, and this has been going on for some time. So Israel is not alone.” Turkey has long-standing territorial disputes with Greece and the Greek Cypriot government in the Aegean and the Mediterranean. Guvenc said Israel has gained the upper hand over Turkey in their rivalry centred on Cyprus. "The Greek Cypriots acquired a very important air defence system from Israel and activated it. They made life far more difficult for the Turkish military, in particular for the Turkish Air Force," he said. "This gives you an idea about the shifting balance of power in the Eastern Mediterranean as a result of Israel taking sides with Cyprus and Greece." Macron and Erdogan find fragile common ground amid battle for influence Tensions over Gaza Despite those rivalries, Turkey and Egypt are finding common ground in their opposition to Israel's war in Gaza and in wider concerns over Israel's growing regional power. In September, Sisi reportedly called Israel an enemy. “There is competition over who is the most dominant and important actor in the Middle East, in the Muslim world in general,” said Lindenstrauss. “I really can't imagine a unified Turkish and Egyptian action against Israel. I can imagine them cooperating to pressure Israel to change its position, which is what is happening now.” Cairo and Ankara remain at odds over Libya, where they back rival governments. But analysts warn that the fallout from the Gaza conflict is increasingly shaping the region's power calculations. Guvenc said the outcome of peace efforts could determine the future balance in the Mediterranean. “We see an alignment of Greece, Greek Cypriots and Israel. But once the Gaza issue is tackled, from an Israeli perspective, Turkey is strategically more important than these two countries,” he said. “But if the strategic makeup of the region may not secure a solution, we may see deterioration in the general situation. Then outside actors will be invited by one side or the other, such as Russia, China or even India, to further complicate the issue.”

The complicated legacy of Pausanias, Spartan regent and commander at Plataea, reveals the razor-thin line between military glory and personal disgrace. When Persian forces under Mardonius threatened Greek freedom in 479 BC, it was Pausanias who stood at the forefront of the Hellenic coalition—a complex alliance of city-states with competing interests and traditions. His story offers a fascinating glimpse into the burdens of command during ancient warfare's most decisive moments.Standing as guardian of Sparta's royal legacy after Leonidas' heroic fall at Thermopylae, Pausanias embodied the Spartan military ethos: disciplined, patient, and tactically conservative. These qualities proved crucial during the tense weeks before battle, as he resisted pressure from more aggressive allies, particularly the Athenians, who pushed for immediate engagement. His calculated restraint preserved the coalition's strength until conditions favored decisive action.The battle itself began with chaos—a nighttime repositioning gone wrong left Greek forces scattered across the plain. When Mardonius seized this opportunity to attack, Pausanias demonstrated remarkable composure under intense Persian assault. Holding firm as arrows darkened the sky, he waited for the perfect moment to order the charge that would ultimately break the Persian line and claim Mardonius' life. This victory marked the definitive end of Persian ambitions on Greek soil.Yet Pausanias' triumph contained the seeds of his undoing. Leading subsequent campaigns in the Aegean, he began adopting Persian customs and displaying an arrogance that alarmed both allies and fellow Spartans. His trajectory from disciplined commander to suspected traitor raises profound questions about how success affects character. Can the same qualities that bring victory in war—decisiveness, authority, self-confidence—become dangerous liabilities in peace? The paradox of Pausanias continues to fascinate: how could the savior of Greece transform so quickly into a figure his own people came to distrust?Whether you're fascinated by ancient military tactics, the psychology of leadership, or the cultural tensions of the Greek world, Pausanias' story offers remarkable insights into how even history's greatest victories can cast long, complicated shadows over those who achieve them. Subscribe now to explore more untold stories from antiquity's most pivotal moments.Support the show

The Sicilian Expedition stands as one of history's most infamous military disasters—a bold gamble that crippled Athenian power and ultimately sealed their fate in the Peloponnesian War. But what drove Athens to stake everything on this distant campaign?When Segesta, a small Sicilian city, came seeking help against their rivals, Athens faced a pivotal choice. Though initially cautious, requesting proof of Segesta's resources and sending scouts to assess the situation, the Athenian assembly's deliberations quickly spiraled beyond simple alliance politics. The real drama unfolded in the clash between two visions of Athens' future: Nicias, the cautious veteran, warning against imperial overreach, and Alcibiades, the brilliant young aristocrat, painting visions of easy conquest and unlimited wealth.What makes this moment so compelling is how Nicias' attempt to discourage the expedition by demanding excessive resources spectacularly backfired. Rather than deterring the assembly, his warnings only inflamed their ambition. The expedition ballooned from 60 ships to an unprecedented armada of 130 triremes and 5,000 hoplites—transforming a limited intervention into an all-or-nothing gamble on conquest.Thucydides frames this decision as inevitable tragedy, the product of Athens' unchecked imperial appetite. Yet other ancient writers suggest the expedition wasn't doomed from inception—its failure stemmed from divided leadership, political sabotage, and cruel twists of fortune. This tension between deterministic failure and contingent possibility makes the Sicilian debate a perfect case study in how democracies make catastrophic military decisions despite warning signs.The expedition's planning reveals deeper truths about Athenian society: their confidence after dominating the Aegean, their hunger for new conquests after the brutal subjugation of Melos, and the factional politics that would soon tear apart their command structure when religious scandals erupted on the eve of departure.Listen as we explore this pivotal moment when Athens reached beyond its grasp—a decision still studied by military strategists today for its timeless lessons about ambition, overextension, and the dangers of democratic war-making. Support the show

This was a fine Thursday crossword by Aidan Deshong -- his 6th for the NYTimes. Jean tore through it, Mike ... did not. The theme, discussed within, was great. The clues were also fine -- 20A, Leveled the playing field, say?, MOWED (awesome!); 55A, Pin number, TEN (

In a time when the sun burned bright over the Aegean, a ragtag chorus of Greek city-states stood shoulder to shoulder against a vast Persian host. Our tale begins in the shadow of fear, as whispers of invasion echoed through Athens, Sparta, and the loyal yet divided Ionian cities. But from the depths of danger arose something rarer: unity. As the Persian lines stretched across the plains of Plataea, Greek leaders faced a crucible of doubt. Their strategy hinged on endurance, terrain, and the courage to trust one another beyond ancient rivalries. The Spartans brought steadiness; Athenian cunning added flexibility; remaining allies offered fierce hearts and hard-won experience. The clash was brutal and precise: hoplites locked shields, spears flashed, and the ground trembled with the march of fate. When the dust settled, the Persian army fractured. The victory was not just tactical; it carried the weight of collective dawns rising over Greek freedom. Plataea sent a clear message to the world: cooperation can turn the tide against overwhelming odds. The Persian threat receded, and with it, the whispers of empire over the Aegean began to waver. In the aftermath, heroes rose and wars shifted, but the spirit endured—an anthem of solidarity over faction, of courage over fear, of a shared homeland stronger than any single city. Plataea became a beacon: a reminder that even the mightiest force falls when united peoples choose to stand together.

Over the past days we've seen tensions rise in the Aegean, with the planned deployment of Turkey's research vessel Piri Reis - which remains docked - raising eyebrows in Athens ahead of an expected meeting between Prime Minister Mitsotakis and President Erdogan on the sidelines of the UN General Assembly. Vassilis Nedos, Kathimerini's diplomatic and defense editor, joins Thanos Davelis to take a closer look at these developments and at the state of Greek-Turkish relations today. You can read the articles we discuss on our podcast here:Measured strain ahead of New YorkAnkara halts ship, Athens on alertBenghazi won't ratify Turkey dealGreek-owned fleet ready to transport more American LNG around the worldPatriarch Bartholomew honored at Capitol Hill

The world's attention will be on New York later this month, as world leaders prepare for the UN General Assembly. The Cyprus problem - one of the longest standing issues before the UN - will also be on the agenda, with UN Secretary General Antonio Guterres scheduled to meet with President Nikos Christodoulides and Turkish Cypriot leader Ersin Tatar. In a slightly different approach to the issue, Michael Rubin, who joins Thanos Davelis, explains that the US has enabled Turkey's occupation in Cyprus by granting Tatar - the illegitimate leader of an illegitimate state - a visa to attend the UNGA, and breaks down how it can correct course.Michael Rubin is a senior fellow at the American Enterprise Institute and director of policy analysis at the Middle East Forum.You can read the articles we discuss on our podcast here:Rubio Should Correct Course on Turkish Occupation of CyprusShould the Foreign Missions Travel Controls Program Extend to Turkey?US targets China's grip on global ports in sweeping maritime missionGreece stages military exercise in Aegean after Turkish survey warningAnkara halts ship, Athens on alert

In this episode Greece Chats returns from summer vacation to start Season 6! In this episode we discuss what is happening in Greece right now! We also discuss Tony's recent wedding in Greece and sailing catamarans around the Aegean.Topics we touch on:-Greece Closing Schools-Birth rates are at an all time low in Greece-Complexities of getting married in Greece-Greece and Giannis Antetokounmpo are making a serious run to win the EuroBasket2025-Is Greece two countries? Is Mykonos its own world?-Should you tip in Greece?-and much much more!Links to services mentioned in episode:Greek Citizenship Acquisition - https://www.getgreece.com/greekcitizenshipProperty Inheritance Assistance - https://www.getgreece.com/property-inheritance

In this Echoes of War Podcast we cover the battle of thermopylae during the Greco-Persian Wars In a sun-bleached dawn, the world watched as Persian banners flickered like blood-touched banners across the Aegean. King Xerxes, hungry for empire, pressed a vast army toward Greece. But beyond the shore, a whisper of resistance gathered: a Greek coalition led by Leonidas, king of Sparta, bound by duty and a stubborn flame of freedom. The Greeks chose a narrow pass at Thermopylae, where steel grit could outweigh numbers. The path demanded courage more than cleverness. Leonidas sent around him a small guard, while the main force held a line of hoplites—shield, spear, and unyielding resolve. The first days blurred into a rhythm of metal sings and shouted oaths, as enemy columns pressed like a tide against a rock. For three days, the Spartans and their allies checked the flood. They bade the women in the villages to keep faith and the ships to wait for a signal that would never come. A fever of rumors rose, yet the friends stood firm, learning to read the wind as if it were a map. Then came a traitor, not of blood but of doubt, revealing a hidden path through the mountains. The Greeks faced a cruel choice: stay and die with honor, or retreat and lose all. They chose the former. The pass was breached, but the stand became legend. Leonidas fell, his spear broken, surrounded by enemies and the roar of a people who would not bow. The rest of Greece endured, inspired by a story that warned tyrants: a single brave heart can turn the tide of history.

Send me a Text Message- please include your contact information so I can respond

Send us a textLufthansas jüngste Tochter City Airlines wächst rasant – und setzt deshalb auf eine ungewöhnliche Lösung: Junge Pilotinnen und Piloten fliegen für mehrere Monate bei Partner-Airlines wie Marabu, Aegean und Chair, um schnell wertvolle Linienerfahrung zu sammeln. So wird der Nachwuchs praxisnah geschult, bevor er fest in den Betrieb von City Airlines einsteigt.Fragen des Tages: Wie steht ihr dazu, dass Lufthansa City Airlines ihre jungen Piloten zu Marabu, Aegean und Chair schickt, um dort Erfahrung zu sammeln, bevor sie zurückkehren? Condor-Kunden können jetzt auch TrueBlue-Punkte sammeln & einlösen – z.B. FRA–JFK ab 19.000 Punkten. Wie findet ihr die neue Partnerschaft?#Lufthansa, #CityAirlines, #Marabu, #Aegean, #ChairAirlines, #AviationNews, #AirbusA320, #Pilot, #FlightTraining, #Aviation00:00 Willkommen zu Frequent Traveller TV01:10 Lufthansa City Airlines Pilotenausbildung03:13 Delta Airlines & Sitzzertifizierung05:46 Qantas Bartverbot für Piloten07:03 ITA Airways Business Class Deal07:52 Condor & JetBlue Partnerschaft08:00 Fragen des TagesTake-OFF 27.08.2025 – Folge 155-2025Stammtisch Termine: https://FQTWorld.as.me/meetupKanalmitglied werden und exklusive Vorteile erhalten:https://www.youtube.com/channel/UCQyWcZxP3MpuQ54foJ_IsgQ/joinHier geht es zu eurem kostenlosen Consulting Link - https://FTCircle.as.me/Damit Du von unserem Wissen profitieren kannst, kannst du ein mindestens 60 minütiges und vor allem auf dich zugeschnittenes Punkte, Meilen, Status Coaching buchen. Nach dem Call bekommst du ein Jahr Zugang zu dieser Gruppe und zahlst so nur 10 Euro pro Monat und kannst sofort profitieren. Hier ist nun der Link zu deinem neuen Punkte, Meilen und Status Deals.MY SOCIALSWhatsApp - https://wa.me/message/54V7X7VO3WOVF1FACEBOOK | Lars F Corsten - https://www.facebook.com/LFCorsten/FACEBOOK | FQT.TV - https://www.facebook.com/FQTTVFACEBOOK | FTCircle - https://www.facebook.com/FTCircleTWITTER | Lars F Corsten - https://twitter.com/LFCorstenINSTAGRAM | Lars F Corsten - https://www.instagram.com/lfcorsten/LINKEDIN - https://www.linkedin.com/in/lfcorsten/Clubhouse - @LFCorsten

Endy Zemenides, HALC's Executive Director, is joined by Michael Rubin, Senior Fellow at the American Enterprise Institute, to break down reports that Israel is closing in on a security deal with Syria as a U.S. envoy meets with Prime Minister Netanyahu, and to analyze what this means for the region, from Turkey to broader U.S. strategy in the Middle East.You can read the article we discuss on our podcast here:Syria's Sharaa confirms 'advanced' talks with Israel on security deal; US envoy meets NetanyahuBirth rate decline a threat to universitiesGreece issues very high wildfire risk alert for Aegean islands and Crete

On this episode of the Human Rights Podcast, LLM student Alessandra Cao speaks with Dr Niamh Keady-Tabbal about the topic of “Drift-backs” in the Aegean, the role of Frontex, and the European Court of Human Rights' (ECtHR) failure to hold Greece accountable for serious human rights violations committed in the Aegean during systematic push-back operations. The conversation first introduces the topic of push-backs at the external borders of the EU, the relatively new phenomenon of “drift-backs” in the Aegean Sea and their relation to European “migration management” strategies as well as human rights concerns arising from these practices. The speakers then dive into the recent European Court of Human Rights decision in the case of GRJ v Greece – a push-back case decided in January 2025, in which Niamh was closely involved – to discuss the evidentiary difficulties arising for applicants in push-back cases, and evaluate the way in which the ECtHR – despite explicitly acknowledging them – has failed to adequately accommodate these difficulties. During the conversation, we referenced a number of cases and academic works. You can read more about the various topics in the links below: #1 Journal Article “Weaponising Rescue: Law and the Materiality of Migration Management in the Aegean” by Niamh Keady-Tabbal and Itamar Mann (Leiden Journal of International Law, 2023): access https://www.cambridge.org/core/journals/leiden-journal-of-international-law/article/weaponizing-rescue-law-and-the-materiality-of-migration-management-in-the-aegean/068B225CF16390CCBA5FFD10FC3CEF8C?utm_campaign=shareaholic&utm_medium=copy_link&utm_source=bookmark #2 Blog Post “Tents at Sea: How Greek Officials Use Rescue Equipment for Illegal Deportations” (Just Security, 2020): access https://www.justsecurity.org/70309/tents-at-sea-how-greek-officials-use-rescue-equipment-for-illegal-deportations/ #3 Forensic Architecture study about the practice of “drift-backs”: access https://forensic-architecture.org/investigation/drift-backs-in-the-aegean-sea #4 Journal Article “The Enforced Disappearance of Migrants” by Valentina Azariva, Amanda Danson Brown, and Itamar Mann (Boston University International Law Journal, 2022): access https://www.bu.edu/ilj/files/2022/08/Vol.-40.1-Azarova-et-al.-online-unprinted.pdf #5 European Court of Human Rights Judgment in GRJ v Greece: access the original judgment in French , and the official summary in English https://hudoc.echr.coe.int/fre#{%22itemid%22:[%22001-243431%22]} https://hudoc.echr.coe.int/fre-press?i=003-8124872-11378023 #6 European Court of Human Rights Judgment in ARE v Greece: access the original judgment in French , and the official summary in English https://hudoc.echr.coe.int/fre#{%22itemid%22:[%22001-238636%22]} https://hudoc.echr.coe.int/fre-press#{%22itemid%22:[%22003-8124877-11378031%22]} The podcast was produced by Alessandra Cao, Gráinne McGrath and Kirsten Larson. Intro Music: 'Smarties Intro - FMA Podcast Suggestions' by Birds for Scale (Attribution - ShareAlike 4.0 international License). Outro Music 'Smarties Outro - FMA Podcast Suggestions' by Birds for Scale (Attribution - ShareAlike 4.0 international License).

Team Elite Recap: Creating the Future with PurposeFresh off the Aegean cruise, this episode captures the energy, insights, and big announcements from Nu Skin's 2025 Team Elite event. Hosts Ryan and Kathy reflect on the power of the Create theme—from launching Prysm iO, a groundbreaking advancement in intelligent wellness, to opening the doors to the massive Indian market. Hear stories of connection, innovation, and how Nu Skin leaders are planting seeds today that will shape lives for years to come.

The past week has seen a number of developments on defense making headlines in Greece, whether it's news that Athens will tap into Europe's SAFE program, or plans that foresee self-sufficient military units on Greece's islands. Vassilis Nedos, Kathimerini's diplomatic and defense editor, joins Thanos Davelis to break down why these moves matter, and look at what else he is paying attention to, including Turkey's deal for Eurofighter jets and its expected response to Greece's new maritime park in the Aegean.You can read the articles we discuss on our podcast here:Greece to tap EU loans to aid defense industriesGreece, 17 EU states apply for SAFE defense financing toolArmed Forces plan foresees self-sufficient army units on islandsGreece awaiting Turkey's marine park responseAthens not surprised by Turkey's Eurofighter acquisitionLibyan coast guards train in Greece under plan to stem migrant flowsErdogan shouldn't bank on Trump 

FIVE MILLENIUM AFTER THE NEO IMPACT, WHAT CIVILIZATIONS REVIVE AND THRIVE?  1/8: After 1177 B.C.: The Survival of Civilizations by  Eric H. Cline  (Author) 1200 BCE MINOAN https://www.amazon.ca/After-1177-B-C-Survival-Civilizations/dp/0691192138 At the end of the acclaimed history 1177 B.C., many of the Late Bronze Age civilizations of the Aegean and Eastern Mediterranean lay in ruins, undone by invasion, revolt, natural disasters, famine, and the demise of international trade. An interconnected world that had boasted major empires and societies, relative peace, robust commerce, and monumental architecture was lost and the so-called First Dark Age had begun. Now, in After 1177 B.C., Eric Cline tells the compelling story of what happened next, over four centuries, across the Aegean and Eastern Mediterranean world. It is a story of resilience, transformation, and success, as well as failures, in an age of chaos and reconfiguration.

Pine Barrens, Aegean cliffs, and Philly Cheese Steaks, In this episode we cover it all! Back in the Saddle again, Nipper and Phil have a catch-up after a long summer break of travels. @NipperRead@Knobtails.IGVenomExchangeRadio on YouTube!VenomExchangeRadio.com

We embark on a summer sojourn to the Aegean to celebrate the creative energy of Athens. We discover the Museum of Cycladic Art, meet shoemaker Le Monde Béryl and talk craftsmanship with Anthologist.See omnystudio.com/listener for privacy information.

First up on the podcast, Contributing Correspondent Andrew Curry joins host Sarah Crespi to discuss a pair of Science papers on kinship and culture in Neolithic Anatolia. The researchers used ancient DNA and isotopes from 8000 to 9000 years ago to show how maternal lines were important in Çatalhöyük culture.   ●     E. Yüncü et al., Female lineages and changing kinship patterns in Neolithic Çatalhöyük, 2025 ●     D. Koptekin et al., Out-of-Anatolia: Cultural and genetic interactions during the Neolithic expansion in the Aegean, 2025   Next on the show, researchers were able to make a synthetic material that changes color in the same way squids do. Georgii Bogdanov, a postdoctoral researcher in the Department of Chemical and Biomolecular Engineering at the University of California, Irvine, talks about how his lab was able to discover the subcellular arrangement of proteins in the squid cells and mimic this structure synthetically using titanium dioxide deposition.   Finally, the latest book in our series on science and death. Books host Angela Saini talks with Tamara Kneese about her book Death Glitch: How Techno-Solutionism Fails Us in This Life and Beyond and whether our families can turn us into chatbots after we die.   This week's episode was produced with help from Podigy.  About the Science Podcast   Authors: Sarah Crespi; Andrew Curry; Angela Saini Learn more about your ad choices. Visit megaphone.fm/adchoices

Dr. Vamsi Velcheti and Dr. Nate Pennell discuss novel treatment approaches in small cell and non-small cell lung cancer that were featured at the 2025 ASCO Annual Meeting. TRANSCRIPT Dr. Vamsi Velcheti: Hello, I'm Dr. Vamsi Velcheti, your guest host of the ASCO Daily News Podcast. I'm a professor of medicine and chief of hematology and oncology at the Mayo Clinic in Jacksonville, Florida. The 2025 ASCO Annual Meeting featured some exciting advancements in small cell lung cancer, targeted therapies for non-small cell lung cancer, and other novel [treatment] approaches. Today, I'm delighted to be joined by Dr. Nate Pennell to discuss some of the key abstracts that are advancing the lung cancer field. Dr. Pennell is the co-director of the Cleveland Clinic Lung Cancer Program and also the vice chair of clinical research at the Taussig Cancer Institute. Our full disclosures are available in the transcript of this episode. Nate, it's great to have you back on the podcast. Thanks so much for being here. Dr. Nate Pennell: Thanks, Vamsi. Always a pleasure. Dr. Vamsi Velcheti: Let's get started, and I think the first abstract that really caught my attention was Abstract 8516, “The Randomized Trial of Relevance of Time of Day of Immunotherapy for Progression-Free and Overall Survival in Patients With Non-Small Cell Lung Cancer.” What are your thoughts about this, Nate? Dr. Nate Pennell: I agree. I thought this was one of the most discussed abstracts, certainly in the lung cancer session, but I think even outside of lung cancer, it got some discussion. So, just to put this in perspective, there have been a number of publications that have all been remarkably consistent, and not just in lung cancer but across multiple cancer types, that immunotherapy, immune checkpoint inhibitors, are commonly used. And all of them have suggested, when looking at retrospective cohorts, that patients who receive immune checkpoint inhibitors earlier in the day – so in the morning or before the early afternoon – for whatever reason, appear to have better outcomes than those who get it later in the day, and this has been repeated. And I think many people just sort of assumed that this was some sort of strange association and that there was something fundamentally different from a prognostic standpoint in people who came in in the morning to get their treatment versus those who came later in the afternoon, and that was probably the explanation. The authors of this randomized trial actually decided to test this concept. And so, about 210 patients with previously untreated advanced non-small cell lung cancer were randomly assigned to get chemo and immune checkpoint inhibitor – either pembrolizumab or sintilimab – and half of them were randomly assigned to get the treatment before 3 PM in the afternoon, and half of them were assigned to get it after 3 PM in the afternoon. And it almost completely recapitulated what was seen in the retrospective cohorts. So, the median progression-free survival in those who got earlier treatment was 13.2 months versus only 6.5 months in those who got it later in the day. So, really enormous difference with a hazard ratio of 0.43, which was statistically significant. And perhaps even more striking, the median overall survival was not reached in the early group versus 17.8 months in the late group with a hazard ratio of 0.43, also highly statistically significant. Even the response rate was 20% higher in the early patients; 75% response rate compared to 56% in the late-time-of-day patients. So very consistent across all measures of efficacy with pretty good matched characteristics across the different groups. And so, I have to tell you, I don't know what to make of this. I certainly was a skeptic about the retrospective series, but now we have a prospective randomized trial that shows essentially the same thing. So, maybe there is a difference between getting treated in the morning, although I have yet to hear someone give a very good mechanistic explanation as to why this would be. What were your thoughts on this? Dr. Vamsi Velcheti: It's indeed fascinating, Nate, and I actually think this was a very interesting abstract. Really, I was caught off guard looking at the data. I mean, if it were a drug, we would be so excited, right? I mean, with those kind of survival benefits. I don't know. I think circadian rhythm probably has something to do with it, like different cytokine profiles at the time of administration. I mean, who knows? But I think it's a randomized trial, and I think I would expect to see a mad rush for treatment appointments early in the morning given this, and at least I want my patients to come in first thing in the morning. It'll be interesting to see. Dr. Nate Pennell: It's important to point out that in this study, everyone got chemo and immunotherapy. And, at least in our cancer center, most patients who are getting platinum-doublet chemotherapy and immunotherapy actually do get treated earlier in the day already, just because of the length of the infusion appointment that's needed. So it really is oftentimes people getting single-agent immunotherapy who are often getting the later, shorter visits. But if you have a choice, I think it would be very reasonable to have people treated earlier in the day. And I do think most of the impressions that I got from people about this is that they would like to see it reproduced but certainly well worth further investigation. And I personally would like to see more investigation into what the rationale would be for this because I still can't quite figure out, yes, if you got it at, say, you know, 5 PM, that's later in the day and I can understand that maybe your immune system is somewhat less receptive at that point than it would be in the morning. But because these checkpoint inhibitors have such long half-lives, it's still in your system the next morning when your immune system is supposedly more receptive. So I don't quite understand why that would be the case. Well, let's move on to the next study. I would like to hear your thoughts on Abstract 8515, “Plasma-Guided, Adaptive First-Line Chemoimmunotherapy for Non-Small Cell Lung Cancer.” Dr. Vamsi Velcheti: Yeah, this was another abstract that seems to be really interesting in my opinion. I think there's kind of a lot of emphasis lately on ctDNA and MRD-based assays to monitor disease. In the lung cancer space, we haven't had a lot of clinical trials looking at this prospectively, and this was one of those pilot studies where they looked at circulating free DNA (cfDNA)-based response-adaptive strategy for frontline patients who are PD-L1 positive. So, patients started with pembrolizumab monotherapy, and based on plasma molecular response after 2 cycles, those patients without response received early treatment intensification with a platinum doublet. So the approach essentially was to reduce the chemotherapy exposure in patients who respond to immunotherapy. And only about 17.5% of the patients on the trial received chemotherapy based on lack of molecular response. So, in this trial, what they found was patients with the cfDNA response had a markedly improved PFS of 16.4 months versus 4.8 months. So essentially, like, this is a really nice study to set a foundation on which we have to do larger studies to incorporate molecular markers trying to look at cfDNA response to inform treatment strategy, either escalation or de-escalation strategies. So, I thought it was a very interesting study. Dr. Nate Pennell: Yeah. I mean, we always have this question for patients, “Should they get immunotherapy alone or combined with chemo?” and I think this certainly is intriguing, suggesting that there may be ways you can monitor people and perhaps rescue those that aren't going to respond to single agent. I'd like to see a randomized trial against, you know, this strategy, perhaps against everyone getting, say, chemoimmunotherapy or make sure that you're not potentially harming people by doing this strategy. But I agree, it's time to move beyond just observing that cell-free DNA is prognostic and important and start using it to actually guide treatment. Dr. Vamsi Velcheti: Yeah, and I would just caution though, like, you know, I think we need more data, but, however, it's certainly a very interesting piece of data to kind of help inform future trials. So, there was another abstract that caught my attention, and I think this would be a very interesting abstract in the EGFR space. Abstract 8506, "Patritumab Deruxtecan (HER3-DXd) in Resistant EGFR-Mutant Advanced Non-Small Cell Lung Cancer Patients After Third-Generation EGFR TKI," it's the HERTHENA-Lung02 study. What do you think about the results of this study? Dr. Nate Pennell: Yeah, this was, I would say, very widely anticipated and ultimately a little disappointing, despite being a positive trial. So, these are patients with EGFR-mutant non-small cell lung cancer who have progressed after a third-generation EGFR TKI like osimertinib. This is really an area of major unmet need. We do have drugs like amivantamab in this space, but still definitely an area where essentially patients move from having a highly effective oral therapy to being in the realm of chemotherapy as their best option. So, this HER3 antibody-drug conjugate, patritumab deruxtecan, had some good single-arm data for this. And we're sort of hoping this would become an available option for patients. This trial was designed against platinum-doublet chemotherapy in this setting and with a primary endpoint of progression-free survival. And it actually was positive for improved progression-free survival compared to chemo with a hazard ratio of 0.77. But when you look at the medians, you can see that the median PFS was only 5.8 versus 5.4 months. It was really a modest difference between the two arms. And on the interim analysis, it appeared that there will not be a difference in overall survival between the two arms. In fact, the hazard ratio at the interim analysis was 0.98 for the two arms. So based on this, unfortunately, the company that developed the HER3-DXd has withdrawn their application to the FDA for approval of the drug, anticipating that they probably wouldn't get past approval without that overall survival endpoint. So, unfortunately, probably not, at least for the near future, going to be a new option for these patients. Dr. Vamsi Velcheti: Yeah, I think this is a space that's clearly an unmet need, and this was a big disappointment, I should say. I think all of us were going into the meeting anticipating some change in the standard of care here. Dr. Nate Pennell: Yeah, I agree. It was something that I was telling patients, honestly, that I was expecting this to be coming, and so now, definitely a bit of a disappointment. But it happens and, hopefully, it will still find perhaps a role or other drugs with a similar target. Certainly an active area. Well, let's leave the EGFR-mutant space and move into small cell. There were a couple of very impactful studies. And one of them was Abstract 8006, “Lurbinectedin Plus Atezolizumab as First-Line Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer, Primary Results from the Phase III IMforte Trial.” So, what was your impression of this? Dr. Vamsi Velcheti: Yeah, I think this is definitely an interesting study, and small cell, I remember those days when we had barely any studies of small cell at ASCO, and now we have a lot of exciting developments in the small cell space. It's really good to see. The IMforte trial is essentially like a maintenance lurbinectedin trial with atezolizumab maintenance. And the study was a positive trial. The primary endpoint was a PFS, and the study showed improvement in both PFS and OS with the addition of lurbinectedin to atezolizumab maintenance. And definitely, it's a positive trial, met its primary endpoint, but I always am a little skeptical of adding maintenance cytotoxic therapies here in this setting. In my practice, and I'd like to hear your opinion, Nate, most patients with small cell after 4 cycles of a platinum doublet, they're kind of really beaten up. Adding more cytotoxic therapy in the maintenance space is going to be tough, I think, for a lot of patients. But also, most importantly, I think this rapidly evolving landscape for patients with small cell lung cancer with multiple new, exciting agents, actually like some FDA-approved like tarlatamab, also like a lot of these emerging therapeutics like I-DXd and other ADCs in this space. You kind of wonder, is it really optimal strategy to bring on like another cytotoxic agent right after induction chemotherapy, or do you kind of delay that? Or maybe have like a different strategy in terms of maintenance. I know that the tarlatamab maintenance trial is probably going to read out at some point too. I think it's a little challenging. The hazard ratio is also 0.73. As I said, it's a positive trial, but it's just incremental benefit of adding lurbi. And also on the trial, we need to also pay attention to the post-progression second-line treatments, number of patients who received tarlatamab or any other investigational agents.  So I think it's a lot of questions still. I'm not quite sure I'd be able to embrace this completely. I think a vast majority of my patients might not be eligible anyway for cytotoxic chemotherapy maintenance right away, but yeah, it's tough. Dr. Nate Pennell: Yeah. I would call this a single and not a home run. It definitely is real. It was a real overall survival benefit. Certainly not surprising that a maintenance therapy would improve progression-free survival. We've known that for a long time in small cell, but first to really show an overall survival benefit. But I completely agree with you. I mean, many people are not going to want to continue further cytotoxics after 4 cycles of platinum-doublet chemo. So I would say, for those that are young and healthy and fly through chemo without a lot of toxicity, I think certainly something worth mentioning. The problem with small cell, of course, is that so many people get sick so quickly while on that observation period after first-line chemo that they don't make it to second-line treatment. And so, giving everyone maintenance therapy essentially ensures everyone gets that second-line treatment. But they also lose that potentially precious few months where they feel good and normal and are able to be off of treatment. So, I would say this is something where we're really going to have to kind of sit and have that shared decision-making visit with patients and decide what's meaningful to them. Dr. Vamsi Velcheti: Yeah, I agree. The next abstract that was a Late-Breaking Abstract, 8000, “Overall Survival of Neoadjuvant Nivolumab Plus Chemotherapy in Patients With Resectable Non-Small Cell Lung Cancer in CheckMate-816.” This was a highly anticipated read-out of the OS data from 816. What did you make of this abstract? Dr. Nate Pennell: Yeah, I thought this was great. Of course, CheckMate-816 changed practice a number of years ago when it first reported out. So, this was the first of the neoadjuvant or perioperative chemoimmunotherapy studies in resectable non-small cell lung cancer. So, just to review, this was a phase 3 study for patients with what we would now consider stage II or stage IIIA resectable non-small cell lung cancer. And they received three cycles of either chemotherapy or chemotherapy plus nivolumab, and that was it. That was the whole treatment. No adjuvant treatment was given afterwards. They went to resection. And patients who received the chemoimmunotherapy had a much higher pathologic complete response rate and a much better event-free survival. And based on this, this regimen was approved and, I think, at least in the United States, widely adopted.  Now, since the first presentation of CheckMate 816, there have been a number of perioperative studies that have included an adjuvant component of immunotherapy – KEYNOTE-671, the AEGEAN study – and these also have shown improved outcomes. The KEYNOTE study with pembrolizumab also with an overall survival benefit. And I think people forgot a little bit about CheckMate-816. So, this was the 5-year overall survival final analysis. And it did show a statistically and, I think, clinically meaningful difference in overall survival with the 3 cycles of neoadjuvant chemo-nivo compared to chemo with a hazard ratio of 0.72. The 5-year overall survival of 65% in the chemo-IO group versus 55% with the chemo alone. So a meaningful improvement. And interestingly, that hazard ratio of 0.72 is very similar to what was seen in the peri-operative pembro study that included the adjuvant component. So, very much still relevant for people who think that perhaps the value of those neoadjuvant treatments might be really where most of the impact comes from this type of approach. They also gave us an update on those with pathologic complete response, showing really astronomically good outcomes. If you have a pathologic complete response, which was more than a quarter of patients, the long-term survival was just phenomenal. I mean, 95% alive at 5 years if they were in that group and suggesting that in those patients at least, the adjuvant treatment may not be all that important.  So, I think this was an exciting update and still leaves very much the open question about the importance of continuing immunotherapy after surgery after the neoadjuvant component. Dr. Vamsi Velcheti: Yeah, I completely agree, Nate. I think the million-dollar question is: “Is there like a population of patients who don't have complete response but like maybe close to complete response?” So, would you like still consider stopping adjuvant IO? I probably would not be comfortable, but I think sometimes, you know, we all have patients who are like very apprehensive of continuing treatments. So, I think that we really need more studies, especially for those patients who don't achieve a complete CR. I think trying to find strategies for like de-escalation based on MRD or other risk factors. But we need more trials in that space to inform not just de-escalation, but there are some patients who don't respond at all to a neoadjuvant IO. So, there may be an opportunity for escalating adjuvant therapies. So, it is an interesting space to watch out for. Dr. Nate Pennell: No, absolutely. Moving to KRAS-mutant space, so our very common situation in patients with non-small cell lung cancer, we had the results of Abstract 8500, “First-Line Adagrasib With Pembrolizumab in Patients With Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer” from the phase 2 portion of the KRYSTAL-7 study. Why was this an interesting and important study? Dr. Vamsi Velcheti: First of all, there were attempts to kind of combine KRASG12C inhibitors in the past with immune checkpoint inhibitors, notably sotorasib with pembrolizumab. Unfortunately, those trials have led to like a lot of toxicity, with increased especially liver toxicity, which was a major issue. This is a phase 2 study of adagrasib in combination with pembrolizumab, and this is a study in the frontline setting in patients with the G12C-mutant metastatic non-small cell lung cancer. And across all the PD-L1 groups, the ORR was 44%, and the median PFS was 11 months, comparable to the previous data that we have seen with adagrasib in this setting. So it's not like a major improvement in clinical efficacy. However, I think the toxicity profile that we were seeing was slightly better than the previous trials in combination with sotorasib, but you still have a fair amount of transaminitis even in the study. At this point, this is not ready for clinical primetime. I don't think we should be using sotorasib or adagrasib in the frontline or even in the second line in combination with checkpoint inhibitors. Combining these drugs with checkpoint inhibitors in the clinical practice might lead to adverse outcomes. So, we need to wait for more data like newer-generation G12C inhibitors which are also being studied in combination, so we'll have to kind of wait for more data to emerge in this space. Dr. Nate Pennell: I agree, this is not immediately practice changing. This is really an attempt to try to combine targeted treatment with immune checkpoint inhibitor. And I agree with you that, you know, it does appear to be perhaps a little bit better tolerated than some of the prior combinations that have tried in this space. The outcomes overall were not that impressive, although in the PD-L1 greater than 50%, it did have a better response rate perhaps than you would expect with either drug alone. And I do think that the company is focusing on that population for a future randomized trial, which certainly would inform this question better. But in the meantime, I agree with you, there's a lot of newer drugs that are coming along that potentially may be more active and better tolerated. And so, I'd say for now, interesting but we'll wait and see. Dr. Vamsi Velcheti: Yeah, so now moving back again to small cell. So, there was a Late-Breaking Abstract, 8008. This is a study of tarlatamab versus chemotherapy as second-line treatment for small cell lung cancer. They presented the primary analysis of the phase III DeLLphi-304 study. What do you think about this? Dr. Nate Pennell: Yeah, I thought this was really exciting. This was, I would say, perhaps the most important lung study that was presented. Tarlatamab is, of course, the anti-DLL3 bispecific T-cell engager compound, which is already FDA approved based on a prior single-arm phase II study, which showed a very nice response rate as a single agent in previously treated small cell lung cancer and relatively manageable side effects, although somewhat unique to solid tumor docs in the use of these bispecific drugs in things like cytokine release syndrome and ICANS, the neurologic toxicities. So, this trial was important because tarlatamab was approved, but there were also other chemotherapy drugs approved in the previously treated space. And so, this was a head-to-head second-line competition comparison between tarlatamab and either topotecan, lurbinectedin, or amrubicin in previously treated small cell patients with a primary endpoint of overall survival. So, a very well-designed trial. And it did show, I think, a very impressive improvement in overall survival with a median overall survival in the tarlatamab group of 13.6 months compared to 8.3 months with chemotherapy, hazard ratio of 0.6. And progression-free survival was also longer at 4.2 months versus 3.2 months, hazard ratio of 0.72. In addition to showing improvements in cancer-related symptoms that were improved in tarlatamab compared to chemotherapy, there was actually also significantly lower rates of serious treatment-related adverse events with tarlatamab compared to chemotherapy. So, you do still see the cytokine release syndrome, which is seen in most people but is manageable because these patients are admitted to the hospital for the first two cycles, as well as a significant number of patients with neurologic side effects, the so-called ICANS, which also can be treated with steroids. And so, I think based upon the very significant improvement in outcomes, I would expect that this should become our kind of standard second-line treatment since it seems to be much better than chemo. However, tarlatamab is definitely a new drug that a lot of places are not used to using, and I think a lot of cancer centers, especially ones that aren't tied to a hospital, may have questions about how to deal with the CRS. So, I'm curious your thoughts on that. Dr. Vamsi Velcheti: Yeah, thank you, Nate. And I completely agree. I think the data looked really promising, and I've already been using tarlatamab in the second-line space. The durability of response and overall, having used tarlatamab quite a bit - like, I participated in some of the early trials and also used it as standard of care - tarlatamab has unique challenges in terms of like need for hospitalization for monitoring for the first few treatments and make sure, you know, we monitor those patients for CRS and ICANS. But once you get past that initial administration and monitoring of CRS, these patients have a much better quality of life, they're off chemotherapy, and I think it's really about the logistics of actually administering tarlatamab and coordination with the hospital and administration in the outpatient setting. It's definitely challenging, but I think it definitely can be done and should be done given what we are seeing in terms of clinical efficacy here. Dr. Nate Pennell: I agree. I think hospital systems now are just going to have to find a way to be able to get this on formulary and use it because it clearly seems to be more effective and generally better tolerated by patients. So, should move forward, I think. Finally, there's an abstract I wanted to ask you about, Abstract 8001, which is the “Neoadjuvant osimertinib with or without chemotherapy versus chemotherapy alone in resectable epidermal growth factor receptor-mutated non-small cell lung cancer: The NeoADAURA Study”. And this is one that I think was also fairly highly anticipated. So, what are your thoughts? Dr. Vamsi Velcheti: You know, I wasn't probably surprised with the results, and I believe we were all expecting a positive trial, and we certainly were handed a positive trial here. It's a phase III trial of osimertinib and chemotherapy or osimertinib in the neoadjuvant space followed by surgery, followed by osimertinib. It's a global phase 3 trial and very well conducted, and patients with stage II to stage IIIB were enrolled in the study. And in the trial, patients who had a neoadjuvant osimertinib with or without chemotherapy showed a significant improvement in major pathologic response rates over chemotherapy alone. And the EFS was also positive for osimertinib and chemotherapy, osimertinib monotherapy as well compared to chemotherapy alone. So overall, the study met its primary endpoint, and I think it sheds light on how we manage our patients with early-stage lung cancer. I think osimertinib, we know that osimertinib is already FDA approved in the adjuvant space, but what we didn't really know is how was osimertinib going to work in the neoadjuvant space. And there are always situations, especially for stage III patients, where we are on the fence about, are these patients already close to being metastatic? They have, like, almost all these patients have micrometastatic disease, even if they have stage III. As we saw in the LAURA data, when you look at the control arm, it was like a very short PFS. Chemoradiation does nothing for those patients, and I think these patients have systemic mets, either gross or micrometastatic disease at onset. So, it's really important to incorporate osimertinib early in the treatment course. And I think, especially for the locally advanced patients, I think it's even more important to kind of incorporate osimertinib in the neoadjuvant space and get effective local control with surgery and treat them with adjuvant. I'm curious to hear your thoughts, Nate. Dr. Nate Pennell: I am a believer and have long been a believer in targeted adjuvant treatments, and, you know, it has always bothered me somewhat that we're using our far and away most effective systemic therapy; we wait until after they go through all their pre-op treatments, they go through surgery, then they go through chemotherapy, and then finally months later, they get their osimertinib, and it still clearly improves survival in the adjuvant setting. Why not just start the osimertinib as soon as you know that the patient has EGFR-mutant non-small cell lung cancer, and then you can move on to surgery and adjuvant treatment afterwards? And I think what was remarkable about this study is that all of these patients almost - 90% in each arm - went to surgery. So, you weren't harming them with the neoadjuvant treatment. And clearly better major pathologic response, nodal downstaging, event-free survival was better. But I don't know that this trial is ever going to show an overall survival difference between neoadjuvant versus just surgery and adjuvant treatment, given how effective the drug is in the adjuvant setting. Nonetheless, I think the data is compelling enough to consider this, certainly for our N2-positive, stage IIIA patients or a IIIB who might be otherwise surgical candidates. I think based on this, I would certainly consider that. Dr. Vamsi Velcheti: Yeah, and especially for EGFR, like even for stage IIIB patients, in the light of the LAURA study, those patients who do not do too well with chemoradiation. So you're kind of delaying effective systemic therapy, as you said, waiting for the chemoradiation to finish. So I think probably time to revisit how we kind of manage these locally advanced EGFR patients. Dr. Nate Pennell: Yep, I agree. Dr. Vamsi Velcheti: Nate, thank you so much for sharing your fantastic insights today on the ASCO Daily News Podcast. It's been an exciting ASCO again. You know, we've seen a lot of positive trials impacting our care of non-small cell lung cancer and small cell lung cancer patients. Dr. Nate Pennell: Thanks for inviting me, Vamsi. Always a pleasure to discuss these with you. Dr. Vamsi Velcheti: And thanks to our listeners for your time today. You will find links to all of the abstracts discussed today in the transcript of the episode. Finally, if you value the insights that you hear from the ASCO Daily News Podcast, please take a moment to rate, review, subscribe wherever you get your podcast. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers:    Dr. Vamsi Velcheti   @VamsiVelcheti    Dr. Nathan Pennell   @n8pennell   Follow ASCO on social media:     @ASCO on Twitter     ASCO on Facebook     ASCO on LinkedIn   ASCO on BlueSky   Disclosures:   Dr. Vamsi Velcheti:   Honoraria: ITeos Therapeutics   Consulting or Advisory Role: Bristol-Myers Squibb, Merck, Foundation Medicine, AstraZeneca/MedImmune, Novartis, Lilly, EMD Serono, GSK, Amgen, Elevation Oncology, Taiho Oncology, Merus   Research Funding (Inst.): Genentech, Trovagene, Eisai, OncoPlex Diagnostics, Alkermes, NantOmics, Genoptix, Altor BioScience, Merck, Bristol-Myers Squibb, Atreca, Heat Biologics, Leap Therapeutics, RSIP Vision, GlaxoSmithKline   Dr. Nathan Pennell:     Consulting or Advisory Role: AstraZeneca, Lilly, Cota Healthcare, Merck, Bristol-Myers Squibb, Genentech, Amgen, G1 Therapeutics, Pfizer, Boehringer Ingelheim, Viosera, Xencor, Mirati Therapeutics, Janssen Oncology, Sanofi/Regeneron    Research Funding (Inst): Genentech, AstraZeneca, Merck, Loxo, Altor BioScience, Spectrum Pharmaceuticals, Bristol-Myers Squibb, Jounce Therapeutics, Mirati Therapeutics, Heat Biologics, WindMIL, Sanofi 

Turkey's latest move to submit a new so-called maritime spatial plan to UNESCO laying claim to half of the Aegean Sea is once again putting the spotlight on its revisionist Blue Homeland doctrine, and raising questions about its commitment to maintaining calm in the region. Constantinos Filis, the director of the Institute of Global Affairs and a professor of international relations at the American College of Greece, joins Thanos Davelis as we take a closer look at this development, breaking down what it means for Greece and the sense of calm that has prevailed over the past few years in the Aegean. You can read the articles we discuss on our podcast here:Turkey draws line of marine influence right down the Aegean SeaAthens navigates the day after the US inserted itself into the wars in IsraelMiddle East conflict's intensity, duration to shape impact on Greek economy Shipping faces elevated risk, Strait of Hormuz closure loomsFM to visit Libya amid maritime tensions

Where in the world am I? Eurail Travel planning   Hi there, I'm Dr. Mary Travelbest. I'm in San Diego now, sharing my best travel ideas and working on another book for you to enjoy: 5 Steps to Solo Travel, Part C. I'm about to launch on a 90-day trip around the world.   Listener Story Spotlight I want to tell you about a listener named Kristen. Kristen loves to travel. She recently received a Fullbright Scholarship and took a trip with her husband and sons to a foreign country, Portugal, for several months. She's full of great travel ideas and will be helpful as I continue to travel and make my adventures more mobile. She's encouraging me to keep going in my travels and is a professor in Southern California. Quick fire FAQ: The FAQ for today is:  Do you find that air travel dries your sinuses? Do you get dry and scratchy throats afterward? Yes, it happens. Let's talk about how to rid yourself of this in advance.    How to avoid the dryness of airline flights? The answer:   My solution is Saline Nasal Spray. I bought the 1.5-oz size for $4.00, which will last my entire trip. Before you get dry sinuses, squirt some in each nostril and then relax as it goes to work. What are the ingredients? Water, sodium chloride, disodium phosphate, benzyl alcohol, sodium phosphate, and benzalkonium chloride. Water and salt. There are three ways to use it: Squeeze twice in each nostril, and it delivers a spray, a stream, and a drop upside down. Take your pick. 60-second confidence challenge   Advice for Active Seniors :  “There is no shame in prioritizing and slowing down vs. overdoing. Most injuries happen when people are rushing. “Go slower, arrive sooner” is a helpful mantra.”  (Ellen McCabe) If you like today's Confidence Challenge, Chapter 2 of my book dives deeper buy it on Amazon or https://www.5stepstosolotravel.com   See Book A for addressing all of these items.   Today's destination is Eurail Travel Planning I said: You are traveling in Europe in the Summer of 2025. You arrive in Athens, Greece, then go to Krakow, Warsaw, Poland, Estonia, Finland, Sweden, Norway, and Denmark, and end in Edinburgh, Scotland, where you leave the EU. You will travel for five weeks. How many days will you want to use the Eurail pass for trains and ferries? Plan the trip, including seat fees and senior discounts with these countries, and suggest other places that would be a good stopping point or worth seeing. I am a solo woman in my prime. Include a mention of the low-cost airlines that I should take when not on the train or ferry.   Answer:   1  Where a Eurail day genuinely saves you money Below is every leg: (a) scenic or pricey at full fare and (b) covered or discounted by the pass if the trip is a low-fare train, like under $10.regional hop, we skip the past day and just pay cash—why burn powder you might need later?    1  Day 3 Athens → Kalabaka  €3 IC seat  Sunset over Meteora cliffs—worth the four-hour train.  2  Day 5 Kalabaka → Thessaloníki  free (regional) No supplement, but one more travel day.  3  Day 9 Krakow → Oświęcim (return) free (regional) Auschwitz day trip; counts once.  4  Day 11 Krakow → Warsaw (EIP)  ~PLN 35 ≈ €8  High‑speed, mandatory seat.  5  Day 13 Warsaw → Gdańsk or Toruń (optional)  PLN 3 ≈ €0.70 Use if you “dive” north.  6  Day 16 Tallinn → Helsinki ferry  deck = free; cabin = ‑20 %  Tallink Silja It counts oas ne travel day.  7  Day 17 Helsinki → Tampere & back  €0–€6 VR seat  Eurail Pendolino; book in app.  8  Day 19 Helsinki o/night ferry → Stockholm  deck = free; cabin –20 % Same Tallink perk.  9  Day 21 Stockholm → Uppsala (return)  €0 (regional) Same‑day out‑and‑back.  10  Day 22 Stockholm → Gothenburg  ≈ €7 SJ seat  Eurail Community 3 h X2000.  11  Day 23 Gothenburg → Oslo  free No reservations.  12  Day 25 Oslo → Bergen  ≈ NOK 50 ≈ €4 seat Bergensbanen panorama.  13  Day 26 Bergen → Flåm train + Nærøyfjord boat  boat covered A rail‑and‑fjord combo.  14  Day 30 Copenhagen → Roskilde day‑trip  ≈ €9 seat  Eurail Vikings have & an easy return.  15  Day 32 Edinburgh → Inverness  £0–£5 seat UK still in the Eurail network.   * Fees are 2ᵈ ‑class, summer 2025 published rates.   Total Eurail travel days = 15 – the cap of the 15‑days‑in‑2‑months Senior Global Pass  2  What about the long, awkward gaps? Why wrestle with two‑day rail marathons when a 90‑minute hop costs less than your hostel?   Segment Suggested airline(s) Typical July fare if bought 3 mo ahead Thessaloníki ✈ Krakow Ryanair, Aegean €55–€85 Warsaw ✈ Tallinn airBaltic, LOT, Ryanair €45–€90 Bergen ✈ Copenhagen Norwegian, SAS €65–€110 Copenhagen ✈ Edinburgh easyJet, Ryanair, Norwegian €40–€80   Question: could you train Thessaloníki→Krakow via Budapest? Yes—but it burns 2‑3 pass days plus €30‑€45 in night‑train supplements. The low‑cost flight is simply cheaper and quicker.   3  Five‑week skeleton itinerary   Week Base & ideas Safety‑first extras for a 65‑yr‑old solo traveler  1 Athens 3 d – dawn Acropolis, Plaka food walk → train to Meteora 2 d (monastery sunsets) → Thessaloníki 2 d for Byzantine walls & waterfront. Central hotels near Syntagma & Aristotelous squares; use the eat taxi app after dark.  2 Fly to Krakow 3 d (+ Auschwitz) → Warsaw 2 d → optional day to Toruń or Gdańsk. Women‑only dorms at Greg & Tom (Krakow) and OkiDoki (Warsaw); trains arrive before dusk.  3 Fly to Tallinn 2 d → ferry to Helsinki 3 d with day‑trip to Tampere—Telliskivi creative city, Suomenlinna flat walks; Bolt taxis for late returns.  4 Night ferry to Stockholm 3 d (+ Uppsala) → train to Gothenburg 2 d → rail to Oslo 2 d. Stockholm hostel “City Backpackers” has curtained bunks; carry Rail Planner live‑trip link to share location.  5 Oslo‑Bergen rail & fjords 3 d → Fly to Copenhagen 3 d (+ Roskilde) → Fly to Edinburgh; finish with Highlands loop 4 d (Inverness, Aviemore hikes) before departure. Fjord cruise boats have good handrails; Scottish B&Bs offer single rooms beside stations.   4  Is the pass still worth it? That's $200-250 saved, plus the flexibility to reroute if wildfires, strikes, or your whims intervene.   5  Quick checklist before you lock it in Buy the Senior Global Pass (15 days/2 months) before prices rise.   Book the four trains with limited seats (EIP Poland, X2000 Sweden, Bergensbanen, Copenhagen reservations) as soon as reservations open—usually 60–90 days in advance.   Use the Rail Planner app to activate travel days on the morning you board; keep two blanks until the very end in case you shuffle plans.   Flights: watch Friday flash sales on Ryanair/Norwegian; they routinely drop

At the 6th Maritime Archaeology Graduate Symposium (MAGS) held in Ioannina, Greece, Professor Lucy Blue spoke with Radomír Tichý from the University of Hradec Králové, Max Šámal (Charles University of Prague) and Aleš Panáček (Archaeopark Všestary) about a series of expeditions called “Monoxylon”. Hear how a team of Czech experimental archaeologists successfully reconstructed and navigated a replica of an 8,000-year-old Neolithic logboat discovered with five other boats at La Marmotta, a submerged lakeshore settlement beneath Lake Bracciano near Rome. Based on the largest, made from an oak trunk measuring over 10 metres in length, it featured transverse reinforcements for hull stability.  Additional objects discovered suggest the use of sails and the presence of obsidian tools from Milos, support the idea that these boats facilitated long distance trade and travel.  The series of expeditions tested the seaworthiness of these ancient designs. Monoxylon IV was paddled by twenty-one crewmembers over 500 kilometres across the Aegean from the island of Samos to the Peloponnese demonstrating that Neolithic communities possessed not only the craftsmanship to fashion such sophisticated vessels, but also the navigational skills to undertake such maritime journeys. The voyages provided practical insights into early human migration, trade routes, and the spread of agricultural practices across the Mediterranean with a profound human story at the heart.  For more information on this project visit the website (https://www.monoxylon.cz/en/), watch the teaser trailer for the upcoming documentary movie (https://youtu.be/6FkAuzf759U?feature=shared) and visit the project YouTube channel (https://www.youtube.com/…524)

From the “Vertical Gas Corridor” to projects in the Eastern Mediterranean, Greece is stepping up its efforts on the energy front. This is placing it at the heart of exciting new developments that will link the East Med with Central Europe and even Ukraine, while drawing the attention of US energy giants like Exxon Mobil and Chevron. Tom Ellis, the editor in chief of Kathimerini's English Edition, joins Thanos Davelis as we break down some of the latest developments on the energy front, and look at what they mean for Greece and its partners in the region.You can read the articles we discuss on our podcast here:Greece on the regional energy mapGreece an ‘ideal connector' in the IMEC corridorGas to flow from Greece to Slovakia, UkraineGreek delegation heads to Egypt amid controversy Ankara eyeing Aegean in new exercise

Expert tour guides share advice for exploring the ancient ruins and seaside villages along Turkey's Aegean coast, the Renaissance wonders of Florence, the sun-drenched Tuscan countryside, and charming Danish towns and islands easily reached on day trips from Copenhagen. For more information on Travel with Rick Steves - including episode descriptions, program archives and related details - visit www.ricksteves.com.

Jacob Richardson's feature film debut The Aegean sees the Queensland based writer-director embrace the Grecian story of a widower, Hector (Costas Mandylor), who finds himself in the orbit of Khristos (Light), a refugee who finds himself in the waters of the Aegean Sea. As Khristos finds himself becoming embedded in Hector's life, he discovers an unexpected bond that will give him a sense of place and purpose that he was missing.In the above interview, Jacob talks about the personal connection to the narrative of The Aegean, how he worked with Costas Mandylor and Light to create their characters, and what it was like working with cinematographer Oliver Hay and composer Allister Harrison on the film. Jacob also talks about his journey from being a film critic to a filmmaker, and how each creative endeavour impacts on the other.The Aegean is released by Radioactive Pictures in Australian cinemas on 16 May 2025. Check your local cinema for screening dates.Follow us on Instagram, Facebook, and Bluesky @thecurbau. We are a completely independent and ad free website that lives on the support of listeners and readers just like you. Visit Patreon.com/thecurbau, where you can support our work from as little as $1 a month. If you are unable to financially support us, then please consider sharing this interview with your podcast loving friends.We'd also love it if you could rate and review us on the podcast player of your choice. Every review helps amplify the interviews and stories from storytellers to a wider audience. Hosted on Acast. See acast.com/privacy for more information.

"Saint Irene was the daughter of a princelet called Licinius; named Penelope by her parents, through a divine revelation she was brought to faith in Christ and at Baptism was renamed Irene. In her zeal for piety she broke in pieces all the idols of her father, who commanded that she be trampled underfoot by horses. But while she remained unharmed, one of the horses rose up and cast down her father, killing him. By her prayer she raised him to life again, and he believed and was baptized. Afterwards, in many journeyings, Saint Irene suffered torments and punishments for her faith, but was preserved by the power of God, while working dread miracles and converting many thousands of souls. At last she came to Ephesus, where she fell asleep in peace, in the first half of the fourth century. Two days after her death, her gravestone was found lifted off, and her grave empty. At least two churches were dedicated to St Irene in Constantinople, and she is the patroness of the Aegean island of Thera, which is commonly called Santorini, a corruption of "Saint Irene." (Great Horologion)   Note: The most famous Agia Irene church in Constantinople is not named after her, but for the Holy Peace (Greek Irene) of God, which is Christ.   The Prologue's account differs in several details. St Nikolai places St Irene in the Balkans in the town of Magedon, in apostolic times rather than the 3rd-4th century. In his account Irene learned the Christian faith from her teacher, Appelianus, and was baptised by the Apostle Timothy himself. He attributes the anger of Irene's father to her refusal to marry rather than her smashing the family idols (though of course she might have done both).

In this episode, we uncover the fascinating story of Shamgar, a lesser-known but mighty figure from Judges 3:31. Was he truly an Israelite judge or a foreign mercenary used by God? Join us as we explore his possible Hurrian or Canaanite roots, his ties to Egypt, and his epic stand against the Philistines, early Sea Peoples of Aegean descent. Through historical insights and biblical context, we reveal how Shamgar may have brought peace to Israel in a time of chaos. Don't miss this deep dive into ancient history, biblical mystery, and divine providence.   If you'd like to support "The History of the Bible", visit our Patreon Page at https://patreon.com/TheHistoryoftheBible. Your feedback is valuable to us! Share your thoughts and insights via our feedback form at https://forms.gle/AtzUReJ8gLuFYPaP8. Let us know how our podcast has impacted you or someone you know by filling out our impact form at https://forms.gle/jr4EdGsqCaFk4qZm8. If you have concerns about any information presented, please inform us via our correction form at https://forms.gle/PiMMkPnJFaa4j5p37.   #BiblePodcast, #BiblicalHistory, #OldTestament, #BookOfJudges, #Shamgar, #Philistines, #SeaPeoples, #AncientIsrael, #BiblicalArchaeology, #ChristianPodcast, #BibleStudyPodcast, #HiddenBibleFigures, #GodsWarrior, #HistoricalBible, #FaithAndHistory, #UnexpectedHeroes, #DivineProvidence, #BiblicalMystery, #Hurrians, #EgyptianMythology   Episode's Sources Bible, NIV Study Bible.  Bible, ESV Study Bible https://www.gotquestions.org/oxgoad-Bible.html https://www.biblicalarchaeology.org/daily/people-cultures-in-the-bible/who-were-philistines-where-did-they-come-from/ https://www.biblicalarchaeology.org/daily/people-cultures-in-the-bible/illuminating-the-philistines-origins/ https://www.worldhistory.org/Philistines/

In January of 1996 Greece and Turkey came close to conflict when the Imia crisis erupted. The US played a critical role in preventing a military escalation through Assistant Secretary of State Richard Holbrooke, and the US ambassadors in Athens and Ankara. Thomas Niles, the US ambassador in Athens at the time who passed away this week, spoke openly about the crisis in the years that followed, noting that the US had made a “big mistake” in not taking a position on Greek sovereignty in the Aegean. Tom Ellis, the editor in chief of Kathimerini's English Edition, joins Thanos Davelis as we look back at the Imia crisis of 1996, the US role in preventing a military confrontation, and its lasting legacy today.You can read the articles we discuss on our podcast here:Thomas Niles, US envoy during Imia crisis, dies at 85Stournaras: Crisis may be Europe's chanceU.S. Announces Deal to Share Ukraine's Mineral WealthUS and Ukraine sign agreement creating investment fund after months of negotiations

A chilled island mix of aegean inspired melodic and deep house featuring tracks and remixes by Anthony Mea, Scott Diaz, Kaskade, T Markakis and more. LeyeT - Impossible Anthony Mea - Ginkla Scott Diaz - Philadelphia AM Five - Away Alexander Popov - Sunset Rays David Folkebrant - Above Ghon - Nimaya Meloko - Me Gusta (Nick Morgan Remix) T Markakis - Sensation John Monkman - Place To Be (String Mix) Killen - Mojo Kaskade - State Of Mind Proff - Love on a Real Train (Tangerine Dream Cover) Bona Fide - Sila Levorica - Moonsheild

The most famous armless statue of all time, ‘Venus de Milo' was discovered by a farmer on the Aegean island of Milos on 8th April, 1829, sparking an international bidding war that saw her eventually donated to the Louvre by Louis XVIII. The French had a particular interest in snapping up a new ancient treasure, having been forced to return many priceless artefacts to their original nations following Napoleon's defeat at Waterloo.  In this episode, Arion, Rebecca and Olly reveal the statue's original blingtastic paintwork; explain why Louis XVIII's obesity delayed its arrival in Paris; and ask what actually happened to Venus's arms… Image: https://flickr.com/photos/sey_alg9/ Further Reading: • ‘Venus de Milo: The Most Famous Armless Statue in the World' (HowStuffWorks, 2020): https://entertainment.howstuffworks.com/arts/artwork/venus-de-milo.htm • ‘How a peasant farmer found the Venus de Milo' (The National, 2020): https://www.thenational.scot/news/18365077.peasant-farmer-found-venus-de-milo/ • ‘The conspiracy behind this famous statue' (VOX, 2020): https://www.youtube.com/watch?v=gs1VWuQEd7Y Love the show? Support us!  Join 

On October 28, 2015, a boat meant for only a few dozen passengers capsized off the coast of Greece. Hundreds of refugees, forced in desperation onto the overloaded boat manned by armed smugglers, were tossed into the sea. The resulting loss of life, the largest in a single day during the crisis in the Aegean, shocked the world.After nearly a decade of research, interviews, and investigation, reporter Jeanne Carstensen has looked to capture every detail of the dramatic twenty-four hours. Her new book is: "A Greek Tragedy: One Day, A Deadly Shipwreck, And the Human Cost of The Refugee Crisis."

5/8: After 1177 B.C.: The Survival of Civilizations by  Eric H. Cline  (Author) https://www.amazon.ca/After-1177-B-C-Survival-Civilizations/dp/0691192138 At the end of the acclaimed history 1177 B.C., many of the Late Bronze Age civilizations of the Aegean and Eastern Mediterranean lay in ruins, undone by invasion, revolt, natural disasters, famine, and the demise of international trade. An interconnected world that had boasted major empires and societies, relative peace, robust commerce, and monumental architecture was lost and the so-called First Dark Age had begun. Now, in After 1177 B.C., Eric Cline tells the compelling story of what happened next, over four centuries, across the Aegean and Eastern Mediterranean world. It is a story of resilience, transformation, and success, as well as failures, in an age of chaos and reconfiguration. 1932 ISHTAR GATE

7/8: After 1177 B.C.: The Survival of Civilizations by  Eric H. Cline  (Author) https://www.amazon.ca/After-1177-B-C-Survival-Civilizations/dp/0691192138 At the end of the acclaimed history 1177 B.C., many of the Late Bronze Age civilizations of the Aegean and Eastern Mediterranean lay in ruins, undone by invasion, revolt, natural disasters, famine, and the demise of international trade. An interconnected world that had boasted major empires and societies, relative peace, robust commerce, and monumental architecture was lost and the so-called First Dark Age had begun. Now, in After 1177 B.C., Eric Cline tells the compelling story of what happened next, over four centuries, across the Aegean and Eastern Mediterranean world. It is a story of resilience, transformation, and success, as well as failures, in an age of chaos and reconfiguration. NDATED RESCUE OF ERECH, BABYLON

6/8: After 1177 B.C.: The Survival of Civilizations by  Eric H. Cline  (Author) https://www.amazon.ca/After-1177-B-C-Survival-Civilizations/dp/0691192138 At the end of the acclaimed history 1177 B.C., many of the Late Bronze Age civilizations of the Aegean and Eastern Mediterranean lay in ruins, undone by invasion, revolt, natural disasters, famine, and the demise of international trade. An interconnected world that had boasted major empires and societies, relative peace, robust commerce, and monumental architecture was lost and the so-called First Dark Age had begun. Now, in After 1177 B.C., Eric Cline tells the compelling story of what happened next, over four centuries, across the Aegean and Eastern Mediterranean world. It is a story of resilience, transformation, and success, as well as failures, in an age of chaos and reconfiguration./8: After 1177 B.C.: The Survival of Civilizations by  Eric H. Cline  (Author) https://www.amazon.ca/After-1177-B-C-Survival-Civilizations/dp/0691192138 At the end of the acclaimed history 1177 B.C., many of the Late Bronze Age civilizations of the Aegean and Eastern Mediterranean lay in ruins, undone by invasion, revolt, natural disasters, famine, and the demise of international trade. An interconnected world that had boasted major empires and societies, relative peace, robust commerce, and monumental architecture was lost and the so-called First Dark Age had begun. Now, in After 1177 B.C., Eric Cline tells the compelling story of what happened next, over four centuries, across the Aegean and Eastern Mediterranean world. It is a story of resilience, transformation, and success, as well as failures, in an age of chaos and reconfiguration. BRONZE AGE HITTITE

8/8: After 1177 B.C.: The Survival of Civilizations by  Eric H. Cline  (Author) https://www.amazon.ca/After-1177-B-C-Survival-Civilizations/dp/0691192138 At the end of the acclaimed history 1177 B.C., many of the Late Bronze Age civilizations of the Aegean and Eastern Mediterranean lay in ruins, undone by invasion, revolt, natural disasters, famine, and the demise of international trade. An interconnected world that had boasted major empires and societies, relative peace, robust commerce, and monumental architecture was lost and the so-called First Dark Age had begun. Now, in After 1177 B.C., Eric Cline tells the compelling story of what happened next, over four centuries, across the Aegean and Eastern Mediterranean world. It is a story of resilience, transformation, and success, as well as failures, in an age of chaos and reconfiguration. BRONZE AGE HITTITE BULL

4/8: After 1177 B.C.: The Survival of Civilizations by  Eric H. Cline  (Author) https://www.amazon.ca/After-1177-B-C-Survival-Civilizations/dp/0691192138 At the end of the acclaimed history 1177 B.C., many of the Late Bronze Age civilizations of the Aegean and Eastern Mediterranean lay in ruins, undone by invasion, revolt, natural disasters, famine, and the demise of international trade. An interconnected world that had boasted major empires and societies, relative peace, robust commerce, and monumental architecture was lost and the so-called First Dark Age had begun. Now, in After 1177 B.C., Eric Cline tells the compelling story of what happened next, over four centuries, across the Aegean and Eastern Mediterranean world. It is a story of resilience, transformation, and success, as well as failures, in an age of chaos and reconfiguration. BRONZE AGE CERAMIC HITTITE OR ASSYRIAN

3/8: After 1177 B.C.: The Survival of Civilizations by  Eric H. Cline  (Author) https://www.amazon.ca/After-1177-B-C-Survival-Civilizations/dp/0691192138 At the end of the acclaimed history 1177 B.C., many of the Late Bronze Age civilizations of the Aegean and Eastern Mediterranean lay in ruins, undone by invasion, revolt, natural disasters, famine, and the demise of international trade. An interconnected world that had boasted major empires and societies, relative peace, robust commerce, and monumental architecture was lost and the so-called First Dark Age had begun. Now, in After 1177 B.C., Eric Cline tells the compelling story of what happened next, over four centuries, across the Aegean and Eastern Mediterranean world. It is a story of resilience, transformation, and success, as well as failures, in an age of chaos and reconfiguration. 1932 BABYLON

2/8: After 1177 B.C.: The Survival of Civilizations by  Eric H. Cline  (Author) https://www.amazon.ca/After-1177-B-C-Survival-Civilizations/dp/0691192138 At the end of the acclaimed history 1177 B.C., many of the Late Bronze Age civilizations of the Aegean and Eastern Mediterranean lay in ruins, undone by invasion, revolt, natural disasters, famine, and the demise of international trade. An interconnected world that had boasted major empires and societies, relative peace, robust commerce, and monumental architecture was lost and the so-called First Dark Age had begun. Now, in After 1177 B.C., Eric Cline tells the compelling story of what happened next, over four centuries, across the Aegean and Eastern Mediterranean world. It is a story of resilience, transformation, and success, as well as failures, in an age of chaos and reconfiguration. BRONZE AGE HITTITE

1/8: After 1177 B.C.: The Survival of Civilizations by  Eric H. Cline  (Author) https://www.amazon.ca/After-1177-B-C-Survival-Civilizations/dp/0691192138 At the end of the acclaimed history 1177 B.C., many of the Late Bronze Age civilizations of the Aegean and Eastern Mediterranean lay in ruins, undone by invasion, revolt, natural disasters, famine, and the demise of international trade. An interconnected world that had boasted major empires and societies, relative peace, robust commerce, and monumental architecture was lost and the so-called First Dark Age had begun. Now, in After 1177 B.C., Eric Cline tells the compelling story of what happened next, over four centuries, across the Aegean and Eastern Mediterranean world. It is a story of resilience, transformation, and success, as well as failures, in an age of chaos and reconfiguration. 1700 BABYLON

GOOD EVENING: The show begins in Dayton, Tennessee where the decision is made to challnge the anti-Darwinian State legislature... Scopes Trial outdoors because of the heat . CBS EYE ON THE WORLD WITH JOHN BATCHELOR FIRST HOUR - SECOND HOUR (9:00-11:00) Extended interview with Brenda Wineapple, discussing "Keeping the Faith: God, Democracy, and the Trial That Riveted a Nation" The 1925 Scopes trial in Dayton, Tennessee Clarence Darrow's defense of John T. Scopes William Jennings Bryan's prosecution Impact on American values and ongoing cultural divisions Early 20th century context of racism, intolerance, and social change THIRD HOUR - FOURTH HOUR (11:00-1:00) Extended interview with Eric H. Cline, discussing "After 1177 B.C.: The Survival of Civilizations" Aftermath of the Late Bronze Age collapse Fall of Aegean and Eastern Mediterranean civilizations Transition through the First Dark Age Stories of resilience and transformation Reconfiguration of civilizations in an age of chaos Each book discussion spans eight 15-minute segments, allowing for in-depth exploration of these historical works and their contemporary relevance.